Q32 Bio
One Broadway, 14th Floor
Cambridge
MA
02142
United States
Website: https://www.q32bio.com/
Email: info@q32bio.com
About Q32 Bio
Q32 Bio is a clinical stage biotechnology company developing therapies targeting powerful regulators of the innate and adaptive immune systems to re-balance immunity in severe autoimmune and inflammatory diseases. Q32 Bio’s lead programs, focused on the IL-7R pathway and complement system, address immune dysregulation to help patients take back control of their lives.
The first-in-human trial for the company’s most advanced program, ADX-914, a fully human anti-IL-7R antibody, is designed to evaluate safety and tolerability and demonstrate proof-of-mechanism. IL-7R has been genetically and biologically validated to drive several T cell-mediated pathological processes in numerous autoimmune diseases.
Q32 Bio’s lead program for innate immunity, ADX-097, is based on a pioneering approach enabling tissue-targeted regulation of the complement system without long-term systemic blockade – a key differentiator versus current complement therapeutics.
8 articles with Q32 Bio
-
Q32 Bio Appoints Dr. Jason Campagna as Chief Medical Officer
3/9/2021
Q32 Bio, a biotechnology company developing therapeutics to restore healthy immune regulation, today announced the appointment of Jason Campagna , M.D., Ph.D. as Chief Medical Officer. Dr. Campagna brings more than 15 years of biotech and pharmaceutical experience to the Q32 Bio executive team
-
It didn’t take long for Jason Campagna to find a new role after departing Intercept Pharmaceuticals last month. Campagna will take on the role of chief medical officer for Q32 Bio.
-
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.
-
Q32 Bio Appoints Experienced Biopharmaceutical Leader Mark Iwicki as Chairman of Board of Directors
12/22/2020
Q32 Bio, a biotechnology company developing therapeutics to restore healthy immune regulation, today announced the appointment of industry leader Mark Iwicki as Chairman of its Board of Directors
-
Q32 Bio rakes in $60 million Series B as they dose their first patient in IL-7R antibody trial.
-
Q32 Bio Closes $60 Million Series B Financing, Advances to Clinical Stage Research in Therapeutics Designed to Restore Immune Homeostasis
10/29/2020
Q32 Bio, a biotechnology company developing biologic therapeutics to restore healthy immune regulation, today announced the completion of a $60 million Series B financing co-led by OrbiMed Advisors and Acorn Bioventures.
-
Q32 Bio Launches to Develop Novel Therapeutics Targeting Regulators of Innate and Adaptive Immunity
5/27/2020
Proprietary tissue-targeted complement platform and best-in-class IL-7R antibody technology to treat patients with severe autoimmune and inflammatory disease; clinical trials begin in 2020
-
With $46 million in Series A financing, Cambridge, Mass.-based Q32 Bio, with a focus on healthy immune regulation, has emerged onto the scene with plans to enter its lead asset into the clinic later this year.